Biomarkers · Inflammation
Alpha-1-Antitrypsin (AAT)
Lower values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).
AAT and risk of death
Published curve higher than the NHANES fitNHANES fit higher
Risk of death relative to the curve's reference value, drawn from the published study (source below).
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
Measured changes in AAT, study by study
1 effect with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Fazirsiran 200 mg subcutaneously on day 1, week 4 and then every 12 weeks in adults with homozygous ZZ AAT deficiency liver disease (SEQUOIA phase 2) | Reduces serum Z-AAT concentration by 94% (least-squares mean) at week 16 vs placebo; -61% and -83% with 25 mg and 100 mg | RCT | Clark VC, Strange C, Strnad P, et al. Fazirsiran for Adults With Alpha-1… |
Sources
- Risk curve: Tabara Y 2021 (PMID 34446826): all-cause HR 2.12 (1.41-3.18) fifth AAT quintile (vs reference quintile). Scaled to published population values.
- Tabara Y, Setoh K, Kawaguchi T, Kosugi S, Nakayama T, Matsuda F. Association between serum α1-antitrypsin levels and all-cause mortality in the general population: the Nagahama study. Sci Rep. 2021;11(1):17241.
Map Alpha-1-Antitrypsin (AAT) against another biomarker.
Related markers: Alpha-1-Antichymotrypsin (AACT) · Antinuclear Antibodies (ANA) · CD4:CD8 T-Cell Ratio · CD8+ T-Cell Count · Erythrocyte Sedimentation Rate (ESR) · Fibrinogen · Growth Differentiation Factor-15 (GDF-15) · High-Sensitivity C-Reactive Protein (hs-CRP)